nodes	percent_of_prediction	percent_of_DWPC	metapath
Tafluprost—PTGFR—corpus luteum—ovarian cancer	0.378	0.383	CbGeAlD
Tafluprost—PTGFR—ovarian follicle—ovarian cancer	0.295	0.299	CbGeAlD
Tafluprost—PTGS2—ovarian follicle—ovarian cancer	0.0811	0.0822	CbGeAlD
Tafluprost—PTGFR—myometrium—ovarian cancer	0.0415	0.0421	CbGeAlD
Tafluprost—PTGFR—uterus—ovarian cancer	0.0269	0.0273	CbGeAlD
Tafluprost—PTGFR—female reproductive system—ovarian cancer	0.0242	0.0245	CbGeAlD
Tafluprost—PTGFR—female gonad—ovarian cancer	0.022	0.0223	CbGeAlD
Tafluprost—PTGFR—testis—ovarian cancer	0.0195	0.0198	CbGeAlD
Tafluprost—PTGFR—lymph node—ovarian cancer	0.0142	0.0143	CbGeAlD
Tafluprost—PTGS2—myometrium—ovarian cancer	0.0114	0.0116	CbGeAlD
Tafluprost—PTGS2—embryo—ovarian cancer	0.011	0.0111	CbGeAlD
Tafluprost—PTGS2—epithelium—ovarian cancer	0.00895	0.00907	CbGeAlD
Tafluprost—PTGS2—uterine cervix—ovarian cancer	0.00888	0.009	CbGeAlD
Tafluprost—PTGS2—endometrium—ovarian cancer	0.00803	0.00814	CbGeAlD
Tafluprost—PTGS2—uterus—ovarian cancer	0.0074	0.0075	CbGeAlD
Tafluprost—PTGS2—female reproductive system—ovarian cancer	0.00665	0.00674	CbGeAlD
Tafluprost—PTGS2—bone marrow—ovarian cancer	0.00628	0.00636	CbGeAlD
Tafluprost—PTGS2—female gonad—ovarian cancer	0.00605	0.00613	CbGeAlD
Tafluprost—PTGS2—vagina—ovarian cancer	0.00601	0.0061	CbGeAlD
Tafluprost—PTGS2—lymph node—ovarian cancer	0.00389	0.00394	CbGeAlD
Tafluprost—PTGFR—Prostaglandin Synthesis and Regulation—ANXA3—ovarian cancer	0.00328	0.247	CbGpPWpGaD
Tafluprost—PTGS2—Prostaglandin Synthesis and Regulation—ANXA3—ovarian cancer	0.00107	0.0805	CbGpPWpGaD
Tafluprost—PTGS2—Overview of nanoparticle effects—PIK3CD—ovarian cancer	0.000226	0.017	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—CYP1B1—ovarian cancer	0.000213	0.016	CbGpPWpGaD
Tafluprost—PTGS2—Arachidonic acid metabolism—CYP1B1—ovarian cancer	0.000199	0.015	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—CD82—ovarian cancer	0.000192	0.0145	CbGpPWpGaD
Tafluprost—PTGS2—Overview of nanoparticle effects—CXCL8—ovarian cancer	0.000189	0.0142	CbGpPWpGaD
Tafluprost—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—ovarian cancer	0.000176	0.0133	CbGpPWpGaD
Tafluprost—PTGS2—Signaling mediated by p38-alpha and p38-beta—ESR1—ovarian cancer	0.000167	0.0125	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—TOP1—ovarian cancer	0.000157	0.0118	CbGpPWpGaD
Tafluprost—PTGS2—S1P1 pathway—VEGFA—ovarian cancer	0.000154	0.0116	CbGpPWpGaD
Tafluprost—PTGS2—S1P1 pathway—MAPK3—ovarian cancer	0.000145	0.0109	CbGpPWpGaD
Tafluprost—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—FASN—ovarian cancer	0.000141	0.0106	CbGpPWpGaD
Tafluprost—PTGS2—S1P1 pathway—MAPK1—ovarian cancer	0.000138	0.0104	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—ESR1—ovarian cancer	0.000134	0.0101	CbGpPWpGaD
Tafluprost—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—SLC2A1—ovarian cancer	0.000134	0.0101	CbGpPWpGaD
Tafluprost—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—ovarian cancer	0.000129	0.0097	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—HSD17B6—ovarian cancer	0.000127	0.00954	CbGpPWpGaD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6ST—ovarian cancer	0.000118	0.00885	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—SOD1—ovarian cancer	0.000113	0.00851	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—GADD45A—ovarian cancer	0.00011	0.00829	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—DLC1—ovarian cancer	0.000108	0.00811	CbGpPWpGaD
Tafluprost—PTGS2—Overview of nanoparticle effects—IL6—ovarian cancer	0.000106	0.00799	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—SOD2—ovarian cancer	0.000102	0.00766	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—CDKN1B—ovarian cancer	9.1e-05	0.00685	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—BCL9—ovarian cancer	8.79e-05	0.00661	CbGpPWpGaD
Tafluprost—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—ovarian cancer	8.72e-05	0.00656	CbGpPWpGaD
Tafluprost—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—ovarian cancer	8.34e-05	0.00628	CbGpPWpGaD
Tafluprost—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—ovarian cancer	8.33e-05	0.00627	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—ovarian cancer	7.57e-05	0.0057	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—GADD45A—ovarian cancer	7.5e-05	0.00564	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—NRAS—ovarian cancer	7.48e-05	0.00563	CbGpPWpGaD
Tafluprost—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—ovarian cancer	7.12e-05	0.00536	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—MYC—ovarian cancer	6.96e-05	0.00524	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—DOK1—ovarian cancer	6.95e-05	0.00523	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—CHEK2—ovarian cancer	6.85e-05	0.00515	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—MAPK1—ovarian cancer	6.81e-05	0.00513	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—EGFR—ovarian cancer	6.81e-05	0.00513	CbGpPWpGaD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—ovarian cancer	6.67e-05	0.00502	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PPP1CC—ovarian cancer	6.53e-05	0.00492	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—TLR4—ovarian cancer	6.47e-05	0.00487	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—KRAS—ovarian cancer	6.44e-05	0.00484	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA1—ovarian cancer	6.42e-05	0.00483	CbGpPWpGaD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—ovarian cancer	6.39e-05	0.00481	CbGpPWpGaD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CXCL8—ovarian cancer	6.16e-05	0.00464	CbGpPWpGaD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—ovarian cancer	6.08e-05	0.00458	CbGpPWpGaD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—ovarian cancer	6.08e-05	0.00458	CbGpPWpGaD
Tafluprost—PTGS2—Disease—HSD17B6—ovarian cancer	5.91e-05	0.00445	CbGpPWpGaD
Tafluprost—PTGFR—G alpha (q) signalling events—PIK3CA—ovarian cancer	5.9e-05	0.00444	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA2—ovarian cancer	5.8e-05	0.00437	CbGpPWpGaD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—ovarian cancer	5.74e-05	0.00432	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	5.72e-05	0.00431	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—CDKN1B—ovarian cancer	5.62e-05	0.00423	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—CCNE1—ovarian cancer	5.62e-05	0.00423	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—ABCB1—ovarian cancer	5.62e-05	0.00423	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—ovarian cancer	5.52e-05	0.00415	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—HRAS—ovarian cancer	5.47e-05	0.00412	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—CCND1—ovarian cancer	5.36e-05	0.00404	CbGpPWpGaD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—ovarian cancer	5.28e-05	0.00397	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—HDAC6—ovarian cancer	4.95e-05	0.00373	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—PPP2R1A—ovarian cancer	4.88e-05	0.00368	CbGpPWpGaD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—ovarian cancer	4.88e-05	0.00367	CbGpPWpGaD
Tafluprost—PTGS2—Disease—CHMP4C—ovarian cancer	4.72e-05	0.00356	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—CXCL8—ovarian cancer	4.69e-05	0.00353	CbGpPWpGaD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—ovarian cancer	4.67e-05	0.00352	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—NRAS—ovarian cancer	4.62e-05	0.00348	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—NME2—ovarian cancer	4.53e-05	0.00341	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—CXCL8—ovarian cancer	4.39e-05	0.0033	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—YAP1—ovarian cancer	4.38e-05	0.0033	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—MYC—ovarian cancer	4.3e-05	0.00324	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—XIAP—ovarian cancer	4.29e-05	0.00323	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	4.29e-05	0.00323	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—CDKN1B—ovarian cancer	4.28e-05	0.00322	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—CASP3—ovarian cancer	4.2e-05	0.00316	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—IL2—ovarian cancer	4.19e-05	0.00315	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—SMARCA4—ovarian cancer	4.18e-05	0.00315	CbGpPWpGaD
Tafluprost—PTGS2—Disease—BCL9—ovarian cancer	4.1e-05	0.00308	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—CCND1—ovarian cancer	4.09e-05	0.00308	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—EREG—ovarian cancer	4.08e-05	0.00307	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	4.05e-05	0.00305	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—KRAS—ovarian cancer	3.98e-05	0.00299	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—MMP9—ovarian cancer	3.97e-05	0.00299	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	3.84e-05	0.00289	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PGR—ovarian cancer	3.83e-05	0.00288	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—PIK3CG—ovarian cancer	3.6e-05	0.00271	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PARP1—ovarian cancer	3.56e-05	0.00268	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—IL6ST—ovarian cancer	3.4e-05	0.00256	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—HRAS—ovarian cancer	3.38e-05	0.00254	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—MAPK3—ovarian cancer	3.37e-05	0.00254	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—MYC—ovarian cancer	3.28e-05	0.00247	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—PIK3CG—ovarian cancer	3.27e-05	0.00246	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—MAPK1—ovarian cancer	3.21e-05	0.00241	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—EGFR—ovarian cancer	3.21e-05	0.00241	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—PIK3CD—ovarian cancer	3.16e-05	0.00238	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	3.15e-05	0.00237	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	3.13e-05	0.00236	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—IL6—ovarian cancer	3.12e-05	0.00234	CbGpPWpGaD
Tafluprost—PTGS2—Disease—PPP1CC—ovarian cancer	3.04e-05	0.00229	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—CYTB—ovarian cancer	2.92e-05	0.00219	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	2.91e-05	0.00219	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PPP2R1A—ovarian cancer	2.89e-05	0.00217	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—PIK3CD—ovarian cancer	2.87e-05	0.00216	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	2.86e-05	0.00215	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	2.85e-05	0.00215	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	2.78e-05	0.00209	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—PIK3CB—ovarian cancer	2.76e-05	0.00208	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	2.75e-05	0.00207	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—TP53—ovarian cancer	2.69e-05	0.00203	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	2.68e-05	0.00202	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—CXCL8—ovarian cancer	2.65e-05	0.00199	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PPP1CC—ovarian cancer	2.55e-05	0.00192	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—BRIP1—ovarian cancer	2.55e-05	0.00192	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—IL2—ovarian cancer	2.53e-05	0.00191	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—PIK3CB—ovarian cancer	2.5e-05	0.00189	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—IL6—ovarian cancer	2.46e-05	0.00185	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	2.42e-05	0.00182	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—CXCL8—ovarian cancer	2.41e-05	0.00181	CbGpPWpGaD
Tafluprost—PTGS2—Disease—HDAC6—ovarian cancer	2.31e-05	0.00174	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—IL2—ovarian cancer	2.3e-05	0.00173	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	2.29e-05	0.00173	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—TERT—ovarian cancer	2.29e-05	0.00172	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	2.23e-05	0.00168	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	2.18e-05	0.00164	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	2.18e-05	0.00164	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CAV1—ovarian cancer	2.12e-05	0.0016	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	2.06e-05	0.00155	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—ESR1—ovarian cancer	2.04e-05	0.00154	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—IL6ST—ovarian cancer	2.01e-05	0.00151	CbGpPWpGaD
Tafluprost—PTGS2—Disease—XIAP—ovarian cancer	2e-05	0.00151	CbGpPWpGaD
Tafluprost—PTGS2—Disease—SMARCA4—ovarian cancer	1.95e-05	0.00147	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—APC—ovarian cancer	1.93e-05	0.00145	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PIK3CG—ovarian cancer	1.93e-05	0.00145	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—NRAS—ovarian cancer	1.93e-05	0.00145	CbGpPWpGaD
Tafluprost—PTGS2—Disease—EREG—ovarian cancer	1.9e-05	0.00143	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	1.89e-05	0.00142	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.86e-05	0.0014	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—MAPK3—ovarian cancer	1.85e-05	0.00139	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	1.83e-05	0.00138	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—MAPK1—ovarian cancer	1.76e-05	0.00132	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—EGFR—ovarian cancer	1.76e-05	0.00132	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—YAP1—ovarian cancer	1.71e-05	0.00129	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PIK3CD—ovarian cancer	1.7e-05	0.00128	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.69e-05	0.00127	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—PIK3CA—ovarian cancer	1.68e-05	0.00127	CbGpPWpGaD
Tafluprost—PTGS2—Disease—FASN—ovarian cancer	1.66e-05	0.00125	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—KRAS—ovarian cancer	1.66e-05	0.00125	CbGpPWpGaD
Tafluprost—PTGS2—Disease—PARP1—ovarian cancer	1.66e-05	0.00125	CbGpPWpGaD
Tafluprost—PTGS2—Disease—SLC2A1—ovarian cancer	1.58e-05	0.00119	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	1.55e-05	0.00116	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—PIK3CA—ovarian cancer	1.53e-05	0.00115	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—ERBB2—ovarian cancer	1.5e-05	0.00113	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.49e-05	0.00112	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—MTOR—ovarian cancer	1.48e-05	0.00111	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PIK3CB—ovarian cancer	1.48e-05	0.00111	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CXCL8—ovarian cancer	1.42e-05	0.00107	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—HRAS—ovarian cancer	1.41e-05	0.00106	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—FASN—ovarian cancer	1.39e-05	0.00105	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CDKN1B—ovarian cancer	1.39e-05	0.00105	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—AKT1—ovarian cancer	1.37e-05	0.00103	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—SLC5A5—ovarian cancer	1.37e-05	0.00103	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CASP3—ovarian cancer	1.36e-05	0.00102	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—IL2—ovarian cancer	1.36e-05	0.00102	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—IL6—ovarian cancer	1.35e-05	0.00102	CbGpPWpGaD
Tafluprost—PTGS2—Disease—PPP2R1A—ovarian cancer	1.34e-05	0.00101	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CCND1—ovarian cancer	1.32e-05	0.000997	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—SLC2A1—ovarian cancer	1.32e-05	0.000997	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CTNNB1—ovarian cancer	1.31e-05	0.000987	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.3e-05	0.000976	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—MMP9—ovarian cancer	1.29e-05	0.000968	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PTEN—ovarian cancer	1.28e-05	0.000962	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—CYP1B1—ovarian cancer	1.27e-05	0.000955	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—AKT1—ovarian cancer	1.25e-05	0.000939	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—VEGFA—ovarian cancer	1.15e-05	0.000869	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—STAT3—ovarian cancer	1.14e-05	0.000861	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—NRAS—ovarian cancer	1.14e-05	0.000858	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PPP2R1A—ovarian cancer	1.13e-05	0.000847	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.12e-05	0.000843	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—MAPK3—ovarian cancer	1.09e-05	0.000822	CbGpPWpGaD
Tafluprost—PTGS2—Disease—TERT—ovarian cancer	1.07e-05	0.000804	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—MYC—ovarian cancer	1.06e-05	0.0008	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—ABCB1—ovarian cancer	1.05e-05	0.000787	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—MAPK1—ovarian cancer	1.04e-05	0.000782	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—EGFR—ovarian cancer	1.04e-05	0.000782	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—TYMS—ovarian cancer	1.03e-05	0.000773	CbGpPWpGaD
Tafluprost—PTGS2—Disease—CAV1—ovarian cancer	9.88e-06	0.000743	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—KRAS—ovarian cancer	9.82e-06	0.000739	CbGpPWpGaD
Tafluprost—PTGS2—Disease—IL6ST—ovarian cancer	9.37e-06	0.000705	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PIK3CA—ovarian cancer	9.02e-06	0.000679	CbGpPWpGaD
Tafluprost—PTGS2—Disease—APC—ovarian cancer	9e-06	0.000677	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—TP53—ovarian cancer	8.73e-06	0.000657	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—HRAS—ovarian cancer	8.35e-06	0.000628	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—CAV1—ovarian cancer	8.27e-06	0.000623	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—IL6—ovarian cancer	7.99e-06	0.000601	CbGpPWpGaD
Tafluprost—PTGS2—Disease—PIK3CD—ovarian cancer	7.91e-06	0.000595	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	7.9e-06	0.000595	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PIK3CG—ovarian cancer	7.54e-06	0.000567	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—AKT1—ovarian cancer	7.37e-06	0.000555	CbGpPWpGaD
Tafluprost—PTGS2—Disease—ERBB2—ovarian cancer	6.99e-06	0.000526	CbGpPWpGaD
Tafluprost—PTGS2—Disease—MTOR—ovarian cancer	6.9e-06	0.000519	CbGpPWpGaD
Tafluprost—PTGS2—Disease—PIK3CB—ovarian cancer	6.9e-06	0.000519	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PIK3CD—ovarian cancer	6.62e-06	0.000499	CbGpPWpGaD
Tafluprost—PTGS2—Disease—CDKN1B—ovarian cancer	6.47e-06	0.000487	CbGpPWpGaD
Tafluprost—PTGS2—Disease—CTNNB1—ovarian cancer	6.11e-06	0.00046	CbGpPWpGaD
Tafluprost—PTGS2—Disease—PTEN—ovarian cancer	5.96e-06	0.000448	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PIK3CB—ovarian cancer	5.77e-06	0.000435	CbGpPWpGaD
Tafluprost—PTGS2—Disease—STAT3—ovarian cancer	5.33e-06	0.000401	CbGpPWpGaD
Tafluprost—PTGS2—Disease—NRAS—ovarian cancer	5.32e-06	0.0004	CbGpPWpGaD
Tafluprost—PTGS2—Disease—MAPK3—ovarian cancer	5.09e-06	0.000383	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PTEN—ovarian cancer	4.99e-06	0.000376	CbGpPWpGaD
Tafluprost—PTGS2—Disease—MYC—ovarian cancer	4.95e-06	0.000373	CbGpPWpGaD
Tafluprost—PTGS2—Disease—MAPK1—ovarian cancer	4.84e-06	0.000365	CbGpPWpGaD
Tafluprost—PTGS2—Disease—EGFR—ovarian cancer	4.84e-06	0.000364	CbGpPWpGaD
Tafluprost—PTGS2—Disease—KRAS—ovarian cancer	4.58e-06	0.000344	CbGpPWpGaD
Tafluprost—PTGS2—Disease—PIK3CA—ovarian cancer	4.2e-06	0.000316	CbGpPWpGaD
Tafluprost—PTGS2—Disease—HRAS—ovarian cancer	3.89e-06	0.000293	CbGpPWpGaD
Tafluprost—PTGS2—Disease—IL6—ovarian cancer	3.72e-06	0.00028	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PIK3CA—ovarian cancer	3.52e-06	0.000265	CbGpPWpGaD
Tafluprost—PTGS2—Disease—AKT1—ovarian cancer	3.43e-06	0.000258	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—AKT1—ovarian cancer	2.88e-06	0.000216	CbGpPWpGaD
